Candida albicans

Overview

Candida albicans is a polymorphic yeast and opportunistic fungal pathogen that is part of the normal human microbiota but can cause disease when host defenses are impaired or local ecological conditions change. It is a major cause of mucosal candidiasis, including oropharyngeal candidiasis, and can also produce invasive fungal infections in immunocompromised individuals. A key feature of its pathogenicity is its ability to form biofilms and to adapt to host niches, including hypoxic microenvironments, which can contribute to persistence and treatment difficulty.

In biomedical research, C. albicans is frequently used as a target organism for antifungal discovery, biomaterials testing, and host–pathogen interaction studies. Recent work has focused on its susceptibility to natural products, nanoparticles, polymer-based delivery systems, and azole-class antifungals, as well as on immune-recognition pathways involving beta-glucan sensing and lectin receptors such as C-type lectin domain containing 6A and C-type lectin domain containing 7A.

Focus of Latest Publications

Recent publications portray Candida albicans as a central test organism in antifungal screening and as a model pathogen for studying mucosal and invasive fungal disease. Several studies evaluated plant-derived extracts and essential oils for direct antifungal activity against C. albicans. For example, an essential oil from fresh leaves of Myrcia spectabilis showed moderate activity and reduced fungal growth by 99.25% in one report, while extracts from Tunisian extremophilic plants and Opuntia ficus-indica oil were also tested against C. albicans with variable antimicrobial effects. Similarly, an ethanolic extract of Coptis chinensis was investigated in the context of oropharyngeal candidiasis, where C. albicans biofilms were linked to a hypoxic microenvironment and modulation of the HIF-1α/IL-17 axis.

Nanotechnology- and formulation-based approaches were also prominent. A eucalyptus oil-decorated phyto-silver nanoparticle-enriched herbal hand sanitizer showed strong antimicrobial activity against C. albicans, and selenium nanoparticles synthesized using olive leaf extract were evaluated for antimicrobial and antibiofilm effects against C. albicans alongside bacteria such as Staphylococcus aureus and Escherichia coli. chitosan-based and polymeric platforms were likewise explored: chitosan-starch biodegradable hydrogels incorporating copper core-shell nanoparticles inhibited C. albicans strains, and core-shell electrospun membranes exerted a mycostatic effect against the yeast. In oral and local drug-delivery research, voriconazole-loaded dissolving microneedle systems were reported to retain antifungal activity against C. albicans, including a fluconazole-resistant strain, while azithromycin-loaded chitosan films were noted to have no antifungal effect on C. albicans, providing a useful negative comparator for oral tissue regeneration platforms.

Several studies addressed antifungal resistance and target-based drug design. A structure-based optimization study of triazole-linked sesamol conjugates targeted CYP51 in C. albicans, explicitly noting the increasing prevalence of azole-resistant C. albicans due to extensive antifungal use. In parallel, a 30 day resistance induction assay and related antifungal development efforts reflect the broader concern that C. albicans can rapidly adapt under drug pressure. Other work evaluated antimicrobial compounds against C. albicans in mixed panels that included Staphylococcus aureus, Bacillus subtilis, Acinetobacter baumannii, Pseudomonas aeruginosa, Aspergillus fumigatus, and Aspergillus niger, underscoring its routine use as a benchmark organism in broad-spectrum screening.

Host immunity and disease modeling were also important themes. A redox-responsive beta-glucan-based vaccine was designed to recruit endogenous antibodies and potentiate antifungal immunity, highlighting beta-glucan as an immunologically relevant fungal component. Another study on DectiSomes targeted human Dectin-1 and Dectin-2 pathways, which are central to recognition of fungal cell wall carbohydrates by antigen-presenting cells. In a separate line of research, Candida albicans cell wall extract (CAWS) was used to induce a Kawasaki disease mouse model, supporting its use as an inflammatory stimulus in experimental immunopathology. Finally, a longitudinal multi-omics pilot study in primary biliary cholangitis reported expansion of opportunistic fungi such as C. albicans in the gut microbiota of UDCA nonresponders, linking the organism to dysbiosis and inflammatory network changes rather than to direct infection alone.